Лечение на анемия

Средства за стимулация на еритропоезата

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (отваря нов прозорец)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Източник‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Статията е индексирана‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (отваря нов прозорец)

High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution. (отваря нов прозорец)

Azzarà A, Carulli G, Galimberti S, Baratè C, Fazzi R, Cervetti G, Petrini M.

Източник‎: Am J Hematol 2011;86(9):762-7.

Статията е индексирана‎: PubMed 21850658

DOI‎: 10.1002/ajh.22111

https://www.ncbi.nlm.nih.gov/pubmed/21850658 (отваря нов прозорец)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (отваря нов прозорец)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Източник‎: Acta Haematol 2007;117(3):162-7.

Статията е индексирана‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (отваря нов прозорец)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (отваря нов прозорец)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Източник‎: Am J Hematol 2013;88(12):990-6.

Статията е индексирана‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (отваря нов прозорец)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (отваря нов прозорец)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Източник‎: J Clin Oncol 2011;29(28):3791-7.

Статията е индексирана‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (отваря нов прозорец)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (отваря нов прозорец)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Източник‎: Cancer 2012;118(3):848-55.

Статията е индексирана‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (отваря нов прозорец)

Management of anemia in cancer patients. (отваря нов прозорец)

Calabrich A, Katz A.

Източник‎: Future Oncol 2011;7(4):507-17.

Статията е индексирана‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (отваря нов прозорец)

Leczenie ostrej białaczki u Świadków Jehowy—opis przypadku i przegląd piśmiennictwa. [Treatment of acute leukemia in Jehovah's Witnesses—a case report and review of the literature.] [Polish, English abstract] (отваря нов прозорец)

Chojnowski K, Trelinski J.

Източник‎: Acta Haematol Pol 2007;38(4):479-84.

Статията е индексирана‎: EMBASE 2008089811

https://web.archive.org/web/20210506152723/https:/pthit.pl/Acta_Haematologica_Polonica,Ostra_bialaczka_Chemioterapia_Swiadkowie_Jehowy_Przetoczenie_krwi,395.html (отваря нов прозорец)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (отваря нов прозорец)

Deger M, Eisterer W, Kutikova L, Salek S.

Източник‎: Support Care Cancer 2013;21(2):485-93.

Статията е индексирана‎: PubMed 22825456

DOI‎: 10.1007/s00520-012-1538-0

https://www.ncbi.nlm.nih.gov/pubmed/22825456 (отваря нов прозорец)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (отваря нов прозорец)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Източник‎: BJU Int 2011;108(10):1582-7.

Статията е индексирана‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (отваря нов прозорец)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (отваря нов прозорец)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Източник‎: J Clin Oncol 2010;28(13):2239-45.

Статията е индексирана‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (отваря нов прозорец)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (отваря нов прозорец)

Ford PA, Grant SJ, Mick R, Keck G.

Източник‎: J Clin Oncol 2015;33(15):1674-9.

Статията е индексирана‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (отваря нов прозорец)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (отваря нов прозорец)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Източник‎: Br J Cancer 2011;105(9):1267-72.

Статията е индексирана‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (отваря нов прозорец)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (отваря нов прозорец)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Източник‎: J Intern Med 2017;281(3):284-99.

Статията е индексирана‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (отваря нов прозорец)

How I treat cancer-associated anemia. (отваря нов прозорец)

Gilreath JA, Rodgers GM

Източник‎: Blood 2020;136(7):801-13.

Статията е индексирана‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (отваря нов прозорец)

Update on safety of ESAs in cancer-induced anemia. (отваря нов прозорец)

Glaspy J.

Източник‎: J Natl Compr Canc Netw 2012;10(5):659-66.

Статията е индексирана‎: PubMed 22570294

https://www.ncbi.nlm.nih.gov/pubmed/22570294 (отваря нов прозорец)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (отваря нов прозорец)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Източник‎: Eur J Haematol. 2023 110(4):354-61.

Статията е индексирана‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (отваря нов прозорец)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (отваря нов прозорец)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Източник‎: Int J Hematol 2015;102(4):401-12.

Статията е индексирана‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (отваря нов прозорец)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (отваря нов прозорец)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Източник‎: Cancer 2013;119(1):107-14.

Статията е индексирана‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (отваря нов прозорец)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (отваря нов прозорец)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Източник‎: J Natl Cancer Inst 2013;105(14):1018-26.

Статията е индексирана‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (отваря нов прозорец)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (отваря нов прозорец)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Източник‎: Cancer Sci 2013;104(4):481-5.

Статията е индексирана‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (отваря нов прозорец)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (отваря нов прозорец)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Източник‎: Br J Haematol 2019;184(2):134-60.

Статията е индексирана‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (отваря нов прозорец)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (отваря нов прозорец)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Източник‎: Support Care Cancer 2012;20(1):159-65.

Статията е индексирана‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (отваря нов прозорец)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (отваря нов прозорец)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Източник‎: Leuk Lymphoma. 2019;60(9):2324-7.

Статията е индексирана‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (отваря нов прозорец)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (отваря нов прозорец)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Източник‎: Oncologist 2010;15(9):935-43.

Статията е индексирана‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (отваря нов прозорец)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (отваря нов прозорец)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Източник‎: Lung Cancer 2012;76(3):478-85.

Статията е индексирана‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (отваря нов прозорец)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (отваря нов прозорец)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Източник‎: Eur J Haematol 2016;97(1):33-8.

Статията е индексирана‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (отваря нов прозорец)

Интравенозно желязо

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (отваря нов прозорец)

Източник‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Статията е индексирана‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (отваря нов прозорец)

Intravenous iron in oncology. (отваря нов прозорец)

Auerbach M, Ballard H.

Източник‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Статията е индексирана‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (отваря нов прозорец)

Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. (отваря нов прозорец)

Buchrits S, Itzhaki O, Avni T, Raanani P, Gafter-Gvili A

Източник‎: J Clin Med. 2022;11(14):4156.

Статията е индексирана‎: PubMed 35887920

DOI‎: 10.3390/jcm11144156

https://pubmed.ncbi.nlm.nih.gov/35887920/ (отваря нов прозорец)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (отваря нов прозорец)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Източник‎: Int J Colorectal Dis 2016;31(3):543-51.

Статията е индексирана‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (отваря нов прозорец)

How I treat cancer-associated anemia. (отваря нов прозорец)

Gilreath JA, Rodgers GM

Източник‎: Blood 2020;136(7):801-13.

Статията е индексирана‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (отваря нов прозорец)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (отваря нов прозорец)

Gilreath JA, Stenehjem DD, Rodgers GM.

Източник‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Статията е индексирана‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (отваря нов прозорец)

Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. (отваря нов прозорец)

Henry DH, Dahl NV, Auerbach MA.

Източник‎: Am J Hematol 2012;87(3):308-10.

Статията е индексирана‎: PubMed 22262486

DOI‎: 10.1002/ajh.22262

https://www.ncbi.nlm.nih.gov/pubmed/22262486 (отваря нов прозорец)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (отваря нов прозорец)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Източник‎: Eur J Haematol. 2023 110(4):354-61.

Статията е индексирана‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (отваря нов прозорец)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (отваря нов прозорец)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Източник‎: Curr Oncol. 2023 24;30(9):7836-51.

Статията е индексирана‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (отваря нов прозорец)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (отваря нов прозорец)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Източник‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Статията е индексирана‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (отваря нов прозорец)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (отваря нов прозорец)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Източник‎: World J Gastroenterol 2014;20(8):1972-85.

Статията е индексирана‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (отваря нов прозорец)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (отваря нов прозорец)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Източник‎: South Asian J Cancer. 2023 15;12(2):93-9.

Статията е индексирана‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (отваря нов прозорец)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (отваря нов прозорец)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Източник‎: J Clin Oncol 2008;26(10):1619-25.

Статията е индексирана‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (отваря нов прозорец)